Impact Biomedical, Inc. · AMEX:IBO
Impact Biomedical — Investor Presentation (January 2025)
19 slides from Impact Biomedical's investor presentation, Jan 29, 2025
Slide 1: New Solutions in Human Health and Wellness
NEW SOLUTIONS IN HUMAN HEALTH AND WELLNESS real] te. www.lmpactBiomedinc.com IMPACT BIOMEDICAL, INC.
Slide 2: Forward-Looking Statements
Nah VAN) Pi HARBOR “allt This presentation contains certain forward-looking statements within the meaning of the federal securities laws. These statements may be made a part of this presentation or by reference to other documents we file with the SEC. Some of the forward-looking statements can be id
Slide 3: Executive Summary
“allt. EXECUTIVE SUMMARY eran n: [BO) Discovers, Confirms, and Patents unique science and te atural and plant-based technologies which can be developed into new offerings in human h ation with external partners through licens development, joint ventures, and oth v v De-tisked pipeline of Pipeline of
Slide 4: Linebacker, Equivir, 3F and Laetose Technologies
LINEBACKER™ LineBacker is a platform electrophilically enhanced polyphenols to induce potency, efficacy, and bioavailability, without compromising safety standards. oul] Ite. IMPACT BIOMEDICAL, INC. EQUIVIR™ Equivir technology is a novel blend of FDA Generally Recognized as A Safe (GRAS) eligible po
Slide 5: Core Insights: Linebacker
Core Insights aan _ LINEBACKER i) Polyphenols are a large family of Modified Myricetin, phenols. They are abundant in plants and structurally a plant derived flavonoid that What is a diverse. Polyphenols include phenolic acids, exhibits strong antioxidant, Polyphenol? _ flavonoids, tannic acid, and
Slide 6: Efficient Development Pathway
Efficient Development Pathway ProPhase COMMERCIAL & MARKET POTENTIAL LABS IMPACT BIOMEDICAL, INC Lung cancer is leading cause of cancer deaths worldwide: Lung cancer (who. int) Global Development X @ F) Colon cancer is the second leading cause & Commercialization Partner: Oncology Neurology eae] Dis
Slide 7: EG (Flavonoids) At a Glance
EG (FLAVONOIDS) At a Glance “"”" Two Discreet Products With Novel blend of generally recognized as safe (GRAS) polyphenols. EQUIVIR $ ee polyp A " ey we Oe ws @ OTC Medication ont ea diene Sera eee ‘Supplement ee on ° “gallnuts ” & RX Applications ° Composition and Method Patents DEVELOPMENT / IP. o
Slide 8: Equivir Positive Preliminary Results
(FLAVONOIDS) Positive Preliminary Results Highlight Promise ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir Commercialistion of Equivir anticipated after second tral is completed roximately 46 incidences of upper atients in the placebo group acquired a viral infec
Slide 9: Functional Fragrances Overview
FUNCTIONAL FRAGRANCES OVERVIEW homens Suite of "functional fragrances” iC) Terpenes are highly aromatic containing specialized botanical ingredients compounds that determine the (e.g., terpenes) with potential application as an smell of many plants and herbs, antiviral or as an insect repellent (e.g
Slide 10: Functional Fragrances: Development & Commercial Opportunity
FUNCTIONAL FRAGRANCES sors Development & Commercial Opportunity CHEMIA COMMERCIAL & Fragrance@Flavor MARKET POTENTIAL ~ ~ ~ * Vector: >unt for more than 17% of Chemia Corp Global Asset available © Malaria is@iparasitic infection transmitted b St. Louis, MO Manufacturing & for immediate Development p
Slide 11: Laetose
Laetose™ @ Sugar Reduction/ ‘Substitute eo Dietary ‘Supplement aa Therapeutics ® What is a Inositol? INTELLECTUAL PROPERTY BENEFITS OF INOSITOL ot © SUPPLEMENTATION Lowering high cholesterol High-Level Snapshot A form of sugar found in your body, in some foods Unique combination of multiple and as a
Slide 12: Immediate Development & Partnership Availability
Immediate Development & Partnership Availability Development Partners Manufacturing established Asset immediately available for partnering/out-licensing Development Status Caloric intake and glycemic index studies planned to support commercial label development COMMERCIAL & w MARKET POTENTIAL Ws an
Slide 13: Upcoming Milestones (FDA/EMA Regulatory Pathway)
I]t. Upcoming Milestones (Foa/ema regulatory Pathway) 2024 | 2025 Oct. Nov. Dec. | Jan. Feb. Mar. a2 a3 a4 1 Q1 2025 Preclinical study anticipated for resul Targeting partnership / outlicen: jing agreement by end of Q1 2025 Linebacker Lactose” Biopharmaceuticals for monotherapy and combination thera
Slide 14: Upcoming Milestones (Direct-to-Consumer)
Upcoming Milestones (oirect-to-consumer) sut licensing agreeme end of Q1 2 _ a) Equivir* /G (Flavonoids) 3F" (Functional Fragrance) ee + Natural Insect Repelient Sugar Substitute/Diet Supplement Antimicrobial Treatments. | OTC Anti-viral Treatments
Slide 15: Intellectual Property
IMPACT BIOMEDICAL, INC. INTELLECTUAL PROPERTY PATENTS ISSUED AND PATENTS PENDING ACROSS ALL PLATFORMS 39 Issued U.S. Patents 50+ Patents Pending EG) Equivir
Slide 16: Executive Officers
EXECUTIVE OFFICERS Fran Chief sutive Officer “allt. Frank D. Heuszel is the CEO of Impact Biomedical, leveraging deep experience in executive management, finance, and strategic development. Previously holding senior roles in commercial banking, he became CEO of parent company DSS, Inc. in 2019. He h
Slide 17: Board of Directors
BOARD OF DIRECTORS “lll. Frank D. Heuszel has served as President and Director ofthe Company since August 2020. Mr Heuszel has served as the Chief Executive Officer of DSS since Apri 11, 2019, and has extensive expertise ina wide array of strategic, business, urnaround, and regulatory matters across
Slide 18: Why Invest in Impact Biomedical Today?
WHY INVEST IN IMPACT BIOMEDICA TODAY? Unique Early-Stage Healthcare Company Leveraging both Regulatory AND Direct to Consumer (OTC) Pathways De-risked opportunity with FOUR Different Platform Technologies leveraging co-development and licensing model Near-term Milestones Across the Entire Portfolio
Slide 19: Contact
eal Tt. IMPACT BIOMEDICAL, INC. www.ImpactBiomedinc.com FOR MORE INFORMATION CONTACT: FRANK D. HEUSZEL, President & CEO fheuszel@impactbiomedinc.com / +1 (281) 415-6576
Impact BioMedical — Investor Presentation (January 2025) on 6ix